A phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy

BACKGROUND: Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate that retains the antitumor effects of trastuzumab while also delivering the cytotoxic antimicrotubule agent, DM1, directly to tumor cells that overexpress human epidermal growth factor receptor 2. The pharmacokinetic (PK) profil...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Medicine (Baltimore)
Prif Awduron: Ji, Dongmei, Shen, Weina, Zhang, Jian, Cao, Junning, Li, Wenhua, Lam, Lisa H., Wu, Fan, Wang, Bei, Li, Zao, Sun, Guofang, Hu, Xichun, Chen, Shang-Chiung
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Lippincott Williams & Wilkins 2020
Pynciau:
5750
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7598804/
https://ncbi.nlm.nih.gov/pubmed/33126339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000022886
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg